Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials.

Fatemeh Zahedipour, Seyede Atefe Hosseini, Mojgan Astaneh, Prashant Kesharwani, Mahmoud Reza Jaafari, Amirhossein Sahebkar

Critical reviews in oncology/hematology 2023 Jul

filter terms:

Peptide vaccines that target vascular endothelial growth factor (VEGF) pathway have shown promising results in inducing strong anti-tumor immune responses with minimal toxicity in various clinical studies. This systematic review was conducted to provide a comprehensive evaluation of the therapeutic efficacy, immune response, survival rate, and side effects of VEGF/VEGF receptor-based peptide vaccines. VEGF/VEGFR2 peptide vaccines were found to be safe and effective in inducing anti-tumor immune responses, while induced moderate clinical benefit. In this regard, further clinical trials are necessary to fully evaluate their clinical effects and the exact correlation between induction of immune response and clinical outcomes. Copyright © 2023 Elsevier B.V. All rights reserved.

Citation

Fatemeh Zahedipour, Seyede Atefe Hosseini, Mojgan Astaneh, Prashant Kesharwani, Mahmoud Reza Jaafari, Amirhossein Sahebkar. Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials. Critical reviews in oncology/hematology. 2023 Jul;187:104032